Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

6.385 +0.275 (+4.50%)
Streaming Delayed Price Updated: 10:51 AM EST, Jan 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 852,188
Open 6.150
Bid (Size) 6.380 (22)
Ask (Size) 6.390 (6)
Prev. Close 6.110
Today's Range 6.150 - 6.420
52wk Range 2.865 - 8.580
Shares Outstanding 67,578,549
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
What 4 Analyst Ratings Have To Say About bluebird bio
 
Via Benzinga
Skechers To Rally 40%? Here Are 10 Other Analyst Forecasts For Monday
Credit Suisse raised the price target for Exelon Corporation (NASDAQ: EXC) from $42 to $46. Credit Suisse analyst Nicholas Campanella maintained an Outperform rating. Exelon shares fell 0.1% to $42.32... 
Via Benzinga

Performance

YTD
-8.00%
-8.00%
1 Month
-8.00%
-8.00%
3 Month
+1.83%
+1.83%
6 Month
+70.27%
+70.27%
1 Year
-18.14%
-18.14%

More News

Read More
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Via The Motley Fool
Tesla, Amazon, bluebird, Netflix, Discover Financial: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
Why Bluebird Bio (BLUE) Stock Is Getting Hammered
Via Benzinga
PNC Financial, bluebird bio And Other Big Stocks Moving Lower On Wednesday
Via Benzinga
Why Is Zomedica (ZOM) Stock Up Today?
Via InvestorPlace
Moderna (MRNA) Stock Pops on RSV Vaccine Trial Results
Via InvestorPlace
Moderna Gets Good News, but Another Biotech Stock Is Falling Again
Via The Motley Fool
Why is Bluebird Bio (BLUE) Stock Down 9% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
2 Stocks That Could Double Your Money in 2023
Via The Motley Fool
bluebird bio Sells Second Priority Review Voucher for $95 Million
From bluebird bio, Inc.
Via Business Wire
Newly Approved Drugs In US Command Over $200,000 On An Average
Via Benzinga
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
From bluebird bio, Inc.
Via Business Wire
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
Via The Motley Fool
After Doubling in the Past 6 Months, Is This Stock a Buy?
Via The Motley Fool
FDA Allows Bluebird Bio To Resume Sickle Cell Disease Studies In Patients Below 18, With Changed Protocol
Via Benzinga
BLUE Stock Alert: What to Know as the FDA Lifts Hold on Bluebird Bio Treatment
Via InvestorPlace
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
From bluebird bio, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.